This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Celgene Corporation
Information provided by (Responsible Party):
UNC Lineberger Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT01412229
First received: August 5, 2011
Last updated: July 5, 2017
Last verified: July 2017
  Purpose
This is a non-randomized, open-label phase II trial of 40 patients with poor prognosis head and neck cancer, defined as surgically unresectable and/or ≥N2b disease and judged appropriate for non-surgical definitive therapy.

Condition Intervention Phase
Head and Neck Cancer Drug: Cetuximab Drug: Nab-paclitaxel Drug: Carboplatin Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Carboplatin, Nab-paclitaxel and Cetuximab for Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Resource links provided by NLM:


Further study details as provided by UNC Lineberger Comprehensive Cancer Center:

Primary Outcome Measures:
  • Clinical Response Rate Following Induction Chemotherapy [ Time Frame: 9 weeks ]
    Evaluation of target lesions via imaging with CT or MRI scans at 2-3 weeks post induction chemotherapy. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions.


Secondary Outcome Measures:
  • Rate of Complete Response Following Induction Chemotherapy [ Time Frame: Baseline evaluation to 3 weeks after induction chemotherapy ]
    Report the rate of complete responses, defined as disappearance of all target lesions, following induction chemotherapy. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions.

  • Progression Free Survival [ Time Frame: 1 year ]
    Rate of Progression Free Survival (Time to death or progression defined by imaging of target lesions via CT or MRI scan post induction chemotherapy and chemoradiotherapy every 3 months for one year)

  • Objective Response Rate (CR+PR) [ Time Frame: 20 weeks ]
    Objective Response Rate as defined by RECIST 1.1 after induction chemotherapy followed by definitive chemoradiation. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Objective Response (OR) = CR + PR.

  • Complete Response Rate (CR) [ Time Frame: 20 weeks ]
    Complete Response Rate as defined by RECIST 1.1 after induction chemotherapy followed by definitive chemoradiation

  • Overall Survival [ Time Frame: 1 year ]
    Rate of Overall Survival

  • Number of Participants With at Least One Grade 3-4 Toxicity [ Time Frame: 9 Weeks ]
    Toxicity will be assessed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.

  • Number of Participants With at Least One Grade 3-4 Toxicity, Listed by Event [ Time Frame: 24 Weeks ]
    Toxicity will be assessed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.

  • Quality of Life [ Time Frame: screening until one year after treatment ]
    Functional Assessment of Cancer Therapy - Head & Neck (FACT-HN) is the FACT-G and a 12 item head and neck cancer specific subscale completed at screening (Screening), 3 weeks post induction chemotherapy (Treatment Break), 7 weeks post concomitant chemoradiotherapy (7 weeks Off Treatment), one year post off-treatment (1 year Off Treatment). The FACT-G is a 27 item measure of general QOL assessing function in 4 domains: physical well-being (PWB), social-family well-being (SFWB), emotional well-being (EWB) and functional well-being (FWB). Items are rated by patients on a Likert scale from 0 to 4 (resulting in potential total scores between 0 and 156). Higher scores represent better QOL.


Enrollment: 40
Study Start Date: February 2012
Estimated Study Completion Date: April 2020
Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment
  • nab-paclitaxel 100mg/m2
  • Carboplatin area under curve (AUC)2 (IV)
  • Cetuximab 400mg/m2 week 1 then 250mg/m2 for six weeks
Drug: Cetuximab
Weekly cetuximab given intravenously for 6 weeks during induction chemotherapy and continue during the 2-3 week break prior to definitive chemoradiotherapy.
Other Name: Erbitux
Drug: Nab-paclitaxel
Weekly nab-paclitaxel given intravenously following cetuximab infusion for 6 weeks.
Other Name: Abraxane
Drug: Carboplatin
Weekly carboplatin given intravenously following nab-paclitaxel infusion for 6 weeks.
Other Name: Paraplatin

Detailed Description:
This is a non-randomized, open-label phase II trial of 40 patients with poor prognosis head and neck cancer, defined as surgically unresectable and/or ≥N2b disease and judged appropriate for non-surgical definitive therapy. Patients must have Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 with good organ function and will be treated with six weekly cycles of carboplatin, nab-paclitaxel and cetuximab prior to scheduled concomitant chemoradiation. The study is designed to evaluate whether this induction regimen can result in an improved response rate (complete response (CR) + partial response (PR)) with less toxicity than the current standard induction docetaxel, cisplatin and 5-fluorouracil (TPF) regimen.
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically or cytologically confirmed SCCHN or poorly differentiated or undifferentiated cancer of the head and neck.
  • Measurable disease.
  • All primary sites are eligible excluding nasopharyngeal.
  • Surgically unresectable and/or N2b or greater nodal disease; Note: surgical unresectability will be defined as the combination of the treating surgeon's judgment of unresectability plus one of the following objective criteria:

    • Encasement of tumor or nodes to the carotid artery or ¾ encasement of the carotid artery.
    • Involvement of prevertebral musculature
    • Invasion of the bone of the skull base
    • Need for glossectomy or extensive glossal resection where functional outcome is considered unacceptable to surgeon or patient
    • Involvement of the cervical spine
    • Severe, unacceptable functional deficit that would result from any proposed definitive surgical resection.
  • ECOG performance status 0-1
  • Prior therapy:

    • Chemotherapy: No prior chemotherapy for the treatment of SCCHN.
    • Platinum chemotherapy: No previous history of carboplatin or cisplatin therapy.
    • Nab-paclitaxel: No previous treatment with nab-paclitaxel or another taxane.
    • Cetuximab: No previous treatment with cetuximab Or another epidermal growth factor receptor (EGFR) inhibitor.
    • Radiation therapy: No prior radiation to the head and neck region.
  • Age > or = 18 years. Men and women are eligible for participation.
  • Must have acceptable organ and marrow function as defined below. Laboratory tests should be completed within 14 days prior to registration:

    • Absolute Neutrophil Count (ANC) > or = 1,500/mm3
    • Platelets > or = 100,000/mm3
    • Hemoglobin (Hgb) > 9g/dL
    • Total bilirubin < or = 1.5mg/dL
    • Albumin > 2.5 g/dL
    • Aspartate aminotransferase (AST)/Alanine Aminotransferase (ALT) < or = 2.5 times institutional upper limit of normal, alkaline phosphatase < 2.5 x upper limit of normal, glomerular filtration rate (GFR) > 30 mL/min (by standard Cockcroft and Gault formula or measured via 24 hour urine collection)
  • No pre-existing neuropathy greater than grade I
  • Women of childbearing potential must have a negative serum or urine pregnancy test performed within 7 days prior to day 1 of study treatment.
  • Women of childbearing potential and men must agree to use adequate contraception prior to study entry, for the duration of study participation and for three months after completing treatment. Adequate contraception is defined as any medically recommended method (or combination of methods) as per standard of care.
  • Patients must have the ability to understand and the willingness to sign a written informed consent document.
  • Patients must have a negative result for preformed immunoglobulin E (IgE) antibodies to galactose-alpha-1,3,-galactose.

Exclusion Criteria:

  • Prior treatment with any of the study medications.
  • Prior radiation to any of the field required to treat the tumor.
  • Any metastatic disease.
  • The patient may have had a prior malignancy but must be disease-free for three years prior to study entry. A history of superficial non-melanoma skin cancer or in situ carcinoma of the cervix less than three years will be allowed.
  • Pregnant or lactating female
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection requiring IV antibiotics, or psychiatric illness/social situations that would limit compliance with study requirements. Cardiac disease such as symptomatic congestive heart failure, unstable angina pectoris, or myocardial infarction will result in exclusion only if active within the past six months. Cardiac dysrhythmia will only result in exclusion if active and symptomatic (for example, rate-controlled atrial fibrillation will not result in exclusion).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01412229

Locations
United States, North Carolina
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States, 27599
United States, Tennessee
Vanderbilt University
Nashville, Tennessee, United States, 37232
United States, Washington
University of Washington
Seattle, Washington, United States, 98194
Sponsors and Collaborators
UNC Lineberger Comprehensive Cancer Center
Celgene Corporation
Investigators
Principal Investigator: Jared Weiss, MD University of North Carolina, Chapel Hill
  More Information

Additional Information:
Responsible Party: UNC Lineberger Comprehensive Cancer Center
ClinicalTrials.gov Identifier: NCT01412229     History of Changes
Other Study ID Numbers: LCCC 1103
Study First Received: August 5, 2011
Results First Received: March 29, 2017
Last Updated: July 5, 2017

Keywords provided by UNC Lineberger Comprehensive Cancer Center:
Head and neck cancer
Phase II
Locally advanced
Squamous Cell
Carboplatin
Nab-paclitaxel
Abraxane
Cetuximab
Induction
Chemotherapy

Additional relevant MeSH terms:
Carcinoma, Squamous Cell
Head and Neck Neoplasms
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Squamous Cell
Neoplasms by Site
Paclitaxel
Albumin-Bound Paclitaxel
Carboplatin
Cetuximab
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on August 17, 2017